Arcus Biosciences (RCUS) CFO reports 6,552-share sale under 10b5-1 plan

Rhea-AI Filing Summary

Arcus Biosciences, Inc. Chief Financial Officer reported a sale of company stock in a routine insider transaction. On 12/31/2025, the reporting person sold 6,552 shares of Arcus Biosciences common stock at a price of $23.38 per share. After this transaction, the insider beneficially owned 67,924 shares of common stock in the company.

The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares according to a predetermined schedule, helping separate trading decisions from day-to-day nonpublic information about the business.

Insider Trade Summary

Net Seller: 6,552 shares ($153,186)

Net Sell 1 txn

Insider Goeltz II Robert C.

Role Chief Financial Officer

Sold 6,552 shs ($153K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,552	$23.38	$153K

Holdings After Transaction: Common Stock — 67,924 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goeltz II Robert C.

(Last) (First) (Middle)

C/O ARCUS BIOSCIENCES, INC.

3928 POINT EDEN WAY

(Street)

HAYWARD CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/31/2025		S(1)		6,552	D	$23.38	67,924	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

	/s/ Carolyn Tang, Attorney-in-Fact	01/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Arcus Biosciences (RCUS) disclose in this filing?

The filing reports that the Chief Financial Officer sold 6,552 shares of Arcus Biosciences common stock on 12/31/2025 at $23.38 per share.

How many Arcus Biosciences (RCUS) shares does the insider own after the reported sale?

Following the reported transaction, the reporting person beneficially owned 67,924 shares of Arcus Biosciences common stock.

Was the Arcus Biosciences (RCUS) insider trade under a Rule 10b5-1 plan?

Yes. The filing states that the sales disclosed were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

What is the role of the reporting person at Arcus Biosciences (RCUS)?

The reporting person is an officer of Arcus Biosciences, serving as the company’s Chief Financial Officer.

Is this Arcus Biosciences (RCUS) insider filing for one person or multiple insiders?

The document indicates it is a Form filed by One Reporting Person, covering only this individual insider.